Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMOTE: Polypill and Stroke Riskometer for Stroke Prevention
NCT05155137Phase 3Recruiting
- Sponsor
- Hospital Moinhos de Vento
- Start
- Dec 2021
- Primary completion
- Dec 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of valsartan, amlodipine and rosuvastatin in stroke and cognitive impairment (4 arms), sponsored by Hospital Moinhos de Vento. Primary endpoints: Incidence of Stroke at 3 years and Rate of Cognitive Decline at 3 years. Started Dec 2021; status: recruiting.
02
Drugs
valsartanamlodipinerosuvastatin
03
Conditions
strokecognitive impairment
Beyond the preview
Go deeper on NCT05155137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05155137.